Boston Scientific Allowance for doubtful accounts increased by 18.8% to $133.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.0%, from $109.00M to $133.00M. Over 4 years (FY 2020 to FY 2024), Allowance for doubtful accounts shows relatively stable performance with a 0.9% CAGR.
other_allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $107.00M | $108.00M | $108.00M | $113.00M | $117.00M | $114.00M | $109.00M | $118.00M | $127.00M | $126.00M | $110.00M | $109.00M | $105.00M | $109.00M | $109.00M | $113.00M | $112.00M | $133.00M |
| QoQ Change | — | +0.9% | +0.0% | +4.6% | +3.5% | -2.6% | -4.4% | +8.3% | +7.6% | -0.8% | -12.7% | -0.9% | -3.7% | +3.8% | +0.0% | +3.7% | -0.9% | +18.8% |
| YoY Change | — | — | — | — | +9.3% | +5.6% | +0.9% | +4.4% | +8.5% | +10.5% | +0.9% | -7.6% | -17.3% | -13.5% | -0.9% | +3.7% | +6.7% | +22.0% |